Umbilical cord stem cells in the treatment of coronavirus pneumonia
Coronavirus-induced pneumonia (inflammation of the lungs) is a new infectious disease known since late 2019, characterized by fever, dry cough, chest tightness. In severe cases, coronavirus pneumonia quickly leads to respiratory failure. A characteristic feature of the disease is a rapid inflammatory response. Specific treatment for coronavirus infection has not yet been developed. Numerous publications have covered cases of successful treatment of coronavirus pneumonia with mesenchymal stem cells. The latter are derived from the umbilical cord, placenta, umbilical cord blood, bone marrow, adipose tissue, dental pulp. The mechanism of therapeutic action of mesenchymal stem cells is their ability to suppress the inflammatory process.
To date, clinical trials of umbilical cord stem and pulp mesenchymal stem cells have been registered in the official international clinical trial database.
On February 14, 2020, a hospital in Wuhan, China, initiated a clinical trial for the treatment of acute coronavirus pneumonia with umbilical cord mesenchymal stem cells. This is a randomized, parallel placebo-controlled trial.
Patients with acute coronavirus pneumonia on the background of symptomatic treatment will receive 3 injections of mesenchymal stem cells isolated from human umbilical cord. Patients will be observed for 96 weeks. After 28 days, the survival rate will be evaluated and, in the course of the study, markers of organ functional activity, C-reactive protein level indicating the inflammatory intensity, other inflammatory markers, infection markers, procalcitonin level, lymphocyte count, T-lymphocyte helpers and suppressors ratio will be determined, possible side effects.
Patients with COVID 19, aged 18-65, may participate in the study, and patients in the age of 17-75 years will be treated in another clinical trial, which also involves the introduction of mesenchymal umbilical cord stem cells and is held in China.
The Ukraine’s first licensed cryobank of the umbilical cord blood, other human tissues and cells, established in 2003 at the Institute of Cell Therapy, provides long-term storage of umbilical cord and placenta mesenchymal stem cells collected at birth, in accordance with international protocols. Specialists of the Institute of Cell Therapy Clinic developed a program for the increase of antiviral defense of the body with the help of stem cells and placental extract.